Shares of Adamis Pharmaceuticals Corp (NASDAQ:ADMP) have been given a consensus rating of “Hold” by the six brokerages that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have issued a buy recommendation on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $6.63.

Several research firms recently commented on ADMP. HC Wainwright set a $7.00 target price on Adamis Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, September 28th. Maxim Group restated a “buy” rating and issued a $13.00 target price on shares of Adamis Pharmaceuticals in a research report on Wednesday, September 12th. Zacks Investment Research upgraded Adamis Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 23rd. Finally, B. Riley cut Adamis Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the company from $7.50 to $2.50 in a research report on Monday, November 12th.

Shares of NASDAQ ADMP opened at $2.79 on Tuesday. The company has a market capitalization of $133.83 million, a P/E ratio of -3.10 and a beta of 0.71. Adamis Pharmaceuticals has a 12-month low of $2.20 and a 12-month high of $5.10.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. increased its position in shares of Adamis Pharmaceuticals by 7.7% during the 2nd quarter. BlackRock Inc. now owns 293,328 shares of the specialty pharmaceutical company’s stock valued at $939,000 after purchasing an additional 20,871 shares during the period. Acropolis Investment Management LLC acquired a new position in shares of Adamis Pharmaceuticals during the 3rd quarter valued at $105,000. Perceptive Advisors LLC acquired a new position in shares of Adamis Pharmaceuticals during the 3rd quarter valued at $481,000. Vanguard Group Inc. increased its position in shares of Adamis Pharmaceuticals by 27.1% during the 3rd quarter. Vanguard Group Inc. now owns 1,637,513 shares of the specialty pharmaceutical company’s stock valued at $5,731,000 after purchasing an additional 348,645 shares during the period. Finally, DekaBank Deutsche Girozentrale grew its holdings in shares of Adamis Pharmaceuticals by 71.4% in the 3rd quarter. DekaBank Deutsche Girozentrale now owns 1,200,000 shares of the specialty pharmaceutical company’s stock worth $3,360,000 after acquiring an additional 500,000 shares during the last quarter. Hedge funds and other institutional investors own 22.37% of the company’s stock.

Adamis Pharmaceuticals Company Profile

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis.

Further Reading: Average Daily Trade Volume Explained

Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.